These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15110983)

  • 21. Topical therapies for glaucoma and ocular hypertension: an update on current practice.
    Rouland JF
    Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S1-4. PubMed ID: 14628758
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical and surgical management of the glaucoma patient.
    Abrams KL
    Clin Tech Small Anim Pract; 2001 Feb; 16(1):71-6. PubMed ID: 11373831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effect of hypertonic hydroxyethyl starch and mannitol on the intraocular pressure in healthy normotensive dogs and the effect of hypertonic hydroxyethyl starch on the intraocular pressure in dogs with primary glaucoma.
    Volopich S; Mosing M; Auer U; Nell B
    Vet Ophthalmol; 2006; 9(4):239-44. PubMed ID: 16771759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension.
    Holló G; Bozkurt B; Irkec M
    Expert Opin Pharmacother; 2009 Aug; 10(12):2015-24. PubMed ID: 19618994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.
    Liu JH; Kripke DF; Weinreb RN
    Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinician's guide to the assessment and management of nonadherence in glaucoma.
    Budenz DL
    Ophthalmology; 2009 Nov; 116(11 Suppl):S43-7. PubMed ID: 19837260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral therapy for ocular viral disease.
    Galle LE
    Vet Clin North Am Small Anim Pract; 2004 May; 34(3):639-53. PubMed ID: 15110976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT.
    Andrés-Guerrero V; Alarma-Estrany P; Molina-Martínez IT; Peral A; Herrero-Vanrell R; Pintor J
    Exp Eye Res; 2009 Mar; 88(3):504-11. PubMed ID: 19056382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review.
    Yee RW
    Curr Opin Ophthalmol; 2007 Mar; 18(2):134-9. PubMed ID: 17301615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
    Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
    Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular hypotensive medications for the treatment of glaucoma.
    Lee DA
    Ophthalmol Clin North Am; 2005 Dec; 18(4):529-38. PubMed ID: 16314217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intraocular pressure in rabbits after administration of 10% L-arginine HCl in 2% Trusopt].
    Veselovský J; Oláh Z; Veselá A; Gressnerová S
    Cesk Slov Oftalmol; 2004 Apr; 60(2):81-8. PubMed ID: 15185445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.
    Trattler W; Noecker RJ; Earl ML
    Adv Ther; 2008 Mar; 25(3):179-89. PubMed ID: 18351298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chart documentation by general physicians of the glaucoma medications taken by their patients.
    Jampel HD; Parekh P; Johnson E; Miller R
    Am J Ophthalmol; 2005 Aug; 140(2):344-5. PubMed ID: 16086971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
    Brandt JD; Beiser JA; Gordon MO; Kass MA;
    Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of eyedrops in glaucoma: how can we help to reduce non-compliance?
    Chawla A; McGalliard JN; Batterbury M
    Acta Ophthalmol Scand; 2007 Jun; 85(4):464. PubMed ID: 17286557
    [No Abstract]   [Full Text] [Related]  

  • 40. Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma.
    Schwartz GF
    Am J Ophthalmol; 2004 Jan; 137(1 Suppl):S1-2. PubMed ID: 14697908
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.